Grant: Collaborative Health Research Projects (NSERC partnered)
Université de Montréal
$122,550.00
Development of an automated blood counter for quantitative molecular imaging applications
FY 2009-10
Summary
"Positron Emission Tomography (PET) and Emission Computed Tomography (SPECT) are well established molecular imaging modalities used in many fields of the biomedical sciences, most notably in neurology, cardiology and oncology. They allow in vivo investigations of biological processes at the molecular level, and provide valuable information on the onset and progression of diseases. PET and SPECT are routinely used for diagnostic purposes and increasingly used to monitor the response to therapy, and in both cases they are key aspects of patient management. These functional imaging modalities also play an important role in the development of new drugs at clinical and preclinical stages.
PET and SPECT images are fundamentally based on a measurable number of nuclear disintegrations and as such are inherently quantitative. The quantitative nature of PET and SPECT can be assessed down to nanomolar concentrations and constitutes a powerful investigation tool for research and clinical purposes. The quantitative nature of PET and SPECT however is typically dismissed in most studies, largely because quantitative protocols are cumbersome and time-consuming. Accurate quantification in PET and SPECT indeed requires frequent assessments of blood activity through direct sampling and measurement in a well-counter, an error-prone task that increases exposure for personnel and potentially interferes with data acquisition. The objective of this project is to develop a device for the automated determination of blood activity for quantitative molecular imaging applications. The device will rely on Cadmium Zinc Telluride (CZT), a room-temperature semi-conductor compatible with clinical requirements such as stability, sturdiness and compactness. This device will dramatically decrease the overhead associated with quantitative PET and SPECT imaging protocols and consequently favor their clinical adoption and development. These studies potentially can provide additional diagnostic clues and valuable information regarding the response to therapy compared to traditional PET and SPECT studies based mostly on visual interpretation and semi-quantitative analysis. This in turn has a direct clinical and economical impact through better patient management. A systematic access to accurate quantitative data in molecular imaging promises to positively change how PET and SPECT studies are used in the clinic and in research protocols.
"
Department
Program
Collaborative Health Research Projects (NSERC partnered)
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
198942
Name
Després Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Unable to allocate
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Development of an automated blood counter for quantitative molecular imaging applications
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$122,550
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Positron Emission Tomography
Abstract
"Positron Emission Tomography (PET) and Emission Computed Tomography (SPECT) are well established molecular imaging modalities used in many fields of the biomedical sciences, most notably in neurology, cardiology and oncology. They allow in vivo investigations of biological processes at the molecular level, and provide valuable information on the onset and progression of diseases. PET and SPECT are routinely used for diagnostic purposes and increasingly used to monitor the response to therapy, and in both cases they are key aspects of patient management. These functional imaging modalities also play an important role in the development of new drugs at clinical and preclinical stages.
PET and SPECT images are fundamentally based on a measurable number of nuclear disintegrations and as such are inherently quantitative. The quantitative nature of PET and SPECT can be assessed down to nanomolar concentrations and constitutes a powerful investigation tool for research and clinical purposes. The quantitative nature of PET and SPECT however is typically dismissed in most studies, largely because quantitative protocols are cumbersome and time-consuming. Accurate quantification in PET and SPECT indeed requires frequent assessments of blood activity through direct sampling and measurement in a well-counter, an error-prone task that increases exposure for personnel and potentially interferes with data acquisition. The objective of this project is to develop a device for the automated determination of blood activity for quantitative molecular imaging applications. The device will rely on Cadmium Zinc Telluride (CZT), a room-temperature semi-conductor compatible with clinical requirements such as stability, sturdiness and compactness. This device will dramatically decrease the overhead associated with quantitative PET and SPECT imaging protocols and consequently favor their clinical adoption and development. These studies potentially can provide additional diagnostic clues and valuable information regarding the response to therapy compared to traditional PET and SPECT studies based mostly on visual interpretation and semi-quantitative analysis. This in turn has a direct clinical and economical impact through better patient management. A systematic access to accurate quantitative data in molecular imaging promises to positively change how PET and SPECT studies are used in the clinic and in research protocols.
"
Competitiondate
200910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Després, Philippe
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $122,550~ $0~